Tirzepatide (dual GLP-1/GIP agonist) produces greater weight loss than semaglutide in head-to-head trials: 2022% versus 1015% body weight reduction
As some researchers are looking at how they can deliver GLP-1s in vivo, others are looking beyond GLP-1 peptides altogether
Seek immediate medical attention for signs of severe dehydration, diabetic ketoacidosis, or severe flank pain with fever
This new weight loss medication takes an innovative approach by tackling the underlying issues that cause metabolic disorders and obesity
Erratum in: Lancet , (2024), 403 (10427), 618
The 2025 Nobel Prize in Physiology or Medicine is awarded to Joel Habener, Svetlana Mojsov, and Jens Juul Holst for their discovery and development of GLP-1based therapeutics, which have revolutionized the treatment of diabetes and obesity worldwide. Well